Bluebird's Zynteglo Gene Therapy Approved By Food and Drug Administration
August 17 2022 - 2:30PM
Dow Jones News
By Kathryn Hardison
The U.S. Food and Drug Administration approved bluebird bio
Inc.'s cell-based gene therapy on Wednesday called Zynteglo.
The therapy is designed for the treatment of adult and pediatric
patients with beta-thalassemia who require regular red blood cell
transfusion. The FDA said Zynteglo is the first cell-based gene
therapy for the blood disorder.
Zynteglo is a one-time gene therapy product administered as a
single dose. The agency said that each dose of Zynteglo is a
customized treatment created using the patient's own cells that are
genetically modified to produce functional beta-globin.
Zynteglo's safety and effectiveness were established in two
multicenter clinical studies that included both adult and pediatric
patients. The most common reactions associated with Zynteglo
included reduced platelet and other blood cell levels, as well as
symptoms like vomiting, alopecia, cough, headache, rash and
more.
Write to Kathryn Hardison at kathryn.hardison@wsj.com
(END) Dow Jones Newswires
August 17, 2022 14:15 ET (18:15 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Mar 2024 to Apr 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Apr 2023 to Apr 2024